Filing Details
- Accession Number:
- 0001638599-16-000970
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-06-01 16:24:06
- Reporting Period:
- 2016-05-27
- Filing Date:
- 2016-06-01
- Accepted Time:
- 2016-06-01 16:24:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1410098 | Cormedix Inc. | CRMD | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1313149 | W Steven Lefkowitz | C/O Cormedix Inc. 1430 Us Highway 206, Suite 200 Bedminster NJ 07921 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 Par Value Per Share | Disposition | 2016-05-27 | 7,800 | $3.04 | 159,599 | No | 4 | S | Direct | |
| Common Stock, $0.001 Par Value Per Share | Disposition | 2016-05-31 | 42,200 | $2.85 | 117,399 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock, $0.001 Par Value Per Share | 174,741 | Indirect | Wade Capital Corporation Money Purchase Plan |
| Common Stock, $0.001 Par Value Per Share | 10,000 | Indirect | Reporting Person's Wife |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 Par Value Per Share | Stock Option (right to buy) | $2.02 | 2024-01-09 | 200,000 | 200,000 | Direct | |
| Common Stock, $0.001 Par Value Per Share | Stock Option (right to buy) | $2.02 | 2024-01-09 | 30,000 | 30,000 | Direct | |
| Common Stock, $0.001 Par Value Per Share | Swries C-3 Non-Voting Convertible Preferred Stock | $1.00 | 45,000 | 4,500 | Direct | ||
| Common Stock, $0.001 Par Value Per Share | Warrant (right to purchase Common Stock) | $0.90 | 2015-01-08 | 2020-01-08 | 22,500 | 22,500 | Direct |
| Common Stock, $0.001 Par Value Per Share | Series C-3 Non-Voting Convertible Preferred Stock | $1.00 | 30,000 | 3,000 | Indirect | ||
| Common Stock, $0.001 Par Value Per Share | Warrant (right to purchase Common Stock) | $0.90 | 2015-01-08 | 2020-01-08 | 15,000 | 15,000 | Indirect |
| Common Stock, $0.001 Par Value Per Share | Stock Option (right to buy) | $0.90 | 2023-03-20 | 120,000 | 120,000 | Direct | |
| Common Stock, $0.001 Par Value Per Share | Stock Option (right to buy) | $0.68 | 2022-12-05 | 150,000 | 100,000 | Direct | |
| Common Stock, $0.001 Par Value Per Share | Stock Option (right to buy) | $1.10 | 2021-08-11 | 30,000 | 30,000 | Direct | |
| Common Stock, $0.001 Par Value Per Share | Stock Option (right to buy) | $5.62 | 2025-03-01 | 50,000 | 50,000 | Direct | |
| Common Stock, $0.001 Par Value Per Share | Stock Option (right to buy) | $1.91 | 2017-09-20 | 75,000 | 75,000 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2024-01-09 | 200,000 | 200,000 | Direct |
| 2024-01-09 | 30,000 | 30,000 | Direct |
| 45,000 | 4,500 | Direct | |
| 2020-01-08 | 22,500 | 22,500 | Direct |
| 30,000 | 3,000 | Indirect | |
| 2020-01-08 | 15,000 | 15,000 | Indirect |
| 2023-03-20 | 120,000 | 120,000 | Direct |
| 2022-12-05 | 150,000 | 100,000 | Direct |
| 2021-08-11 | 30,000 | 30,000 | Direct |
| 2025-03-01 | 50,000 | 50,000 | Direct |
| 2017-09-20 | 75,000 | 75,000 | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.08, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.85 to $2.88, inclusive.
- The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control).
- The options vested 100% on January 10, 2014.
- The options vest in full on the first anniversary of the date of grant.
- On January 8, 2014, the reporting person acquired in a private placement (i) 4,500 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
- On January 8, 2014, the reporting person, through his ownership in Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control), acquired in a private placement (i) 3,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
- These options vest quarterly over two years beginning June 13, 2013.
- These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occuured on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
- The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
Billionaire Hedge Funds
